Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521948 | 0.87 | KDM4E (0.56) | SMN1; SMN2KDM4ERAB9ATP53HSD17B10 | |
| SCHEMBL27729965 | 0.86 | KMT2A (0.54) | SMN1; SMN2KDM4ERAB9ATP53HSD17B10 | |
| SCHEMBL23574669 | 0.85 | CA12 (0.52) | SMN1; SMN2KDM4ERAB9ATP53HSD17B10 | |
| SCHEMBL10073336 | 0.83 | KDM4E (0.81) | SMN1; SMN2KDM4ERAB9ATP53HSD17B10 | |
| SCHEMBL23574375 | 0.83 | KDM4E (0.60) | SMN1; SMN2KDM4ERAB9ATP53HSD17B10 | |
| SCHEMBL5166558 | 0.83 | SMN1; SMN2 (0.75) | SMN1; SMN2KDM4ERAB9ATP53KMT2A | |
| SCHEMBL10375312 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4ERAB9ATP53HSD17B10 | |
| SCHEMBL4395939 | 0.82 | KDM4E (0.65) | SMN1; SMN2KDM4ERAB9ATP53HSD17B10 | |
| SCHEMBL23574212 | 0.81 | KDM4E (0.47) | SMN1; SMN2KDM4ERAB9ATP53HSD17B10 | |
| SCHEMBL15150048 | 0.80 | GAA (0.50) | SMN1; SMN2KDM4ERAB9ATP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7161024-B2 | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161024-B2 | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7161024-B2 | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1644313-A2 | PROCESS FOR THE PREPARATION AND PURIFICATION OF 2-(ALKOXYALKYLIDENE)-3-KETOALKANOIC ACID ESTERS FROM 3-KETOALKANOIC ACID ESTERS | SCHERING CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050027140-A1 | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters | SCHERING CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2005007608-A2 | PROCESS FOR THE PREPARATION AND PURIFICATION OF 2-(ALKOXYALKYLIDENE)-3-KETOALKANOIC ACID ESTERS FROM 3-KETOALKANOIC ACID ESTERS | SCHERING CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027140-A1 | Process for the preparation and purification of 2-(alkoxyalkylidene)-3-ketoalkanoic acid esters from 3-ketoalkanoic acid esters | ACKR3, CCR5, CCRL2 | SMN1; SMN2 4564/4885KDM4E 1085/4885RAB9A 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.